23.02.2006 – 08:20

Zeltia Group

Zeltia: Report at 31 December 2005

Madrid (ots/PRNewswire)

Group:

• Capital increase at Zeltia. The placement of 10.75 million new shares among qualified international investors raised 65 million euro
• R&D expenditure up 24%
• Net revenues in 2005: 72 million euro
• Net cash position at 31 December 2005: 93 million euro net of short-term financial debt and 51 million euro net of total financial debt

PharmaMar:

• Yondelis(R):
• Phase III pivotal trial on ovarian cancer commenced
• Recruitment for the pivotal randomised trial on soft-tissue sarcoma was completed
• Aplidin(R):
• Phase II studies on prostate and bladder cancer commenced
• Combination studies with other chemotherapy agents commenced
• Zalypsis(R), PharmaMar's fifth compound to reach clinical trials
• PM02734 is PharmaMar's sixth compound to reach clinical trials

Xylazel:

• Launched a full range of Xylazel-brand wood protecting paints and varnishes.
• Conclusion of licensing and marketing agreement with ICI.

Isabel Lozano
    Chief Executive Officer
    PHARMAMAR, S.A.
    C/ Reyes, 1.
    Colmenar Viejo Madrid
    Telephone +34-91-846-60-00
    Catherine Moukheibir
    Head of Capital Market Strategy
    ZELTIA, S.A.
    José Abascal, 2. Madrid
    Telephone +34-91-444-45-00
    Ma Luisa de Francia
    Chief Financial Officer
    ZELTIA, S.A.
    José Abascal, 2. Madrid
    Telephone +34-91-444-45-00

For a copy of the full results, please refer to www.zeltia.com

Contact:

Isabel Lozano, Chief Executive Officer, PHARMAMAR, S.A., C/ Reyes,
1., Colmenar Viejo, Madrid, Telephone +34-91-846-60-00; Catherine
Moukheibir, Head of Capital Market Strategy, ZELTIA, S.A., José
Abascal, 2. Madrid, Telephone +34-91-444-45-00; Ma Luisa de Francia,
Chief Financial Officer, ZELTIA, S.A., José Abascal, 2. Madrid,
Telephone +34-91-444-45-00